Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

NSCLC 1

Interventions

Carboplatin 7Pemetrexed 6osimertinib 5Drug Therapy 5tislelizumab 3anlotinib 3aflutinib 3Radiotherapy 3Radiosurgery 3Paclitaxel 3Cisplatin 3toripalimab 2pembrolizumab 2camrelizumab 2apatinib 2Surgical Procedures, Operative 2S 1 (combination) 2HM781-36B 2Chemotherapy, Adjuvant 2Chemoradiotherapy 2trilaciclib 1surufatinib 1sintilimab 1rezivertinib 1lenvatinib 1icotinib 1famitinib 1envafolimab 1dacomitinib 1cemiplimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × NSCLC × rezivertinib × Clear all
NCT03812809 2022-05-19

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

Beta Pharma, Inc.

Phase 2 Completed
226 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡